Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX)Article Published on 2022-10-062022-11-15 Journal: Rheumatology (Oxford, England) [Category] [DOI] 10.1093/rheumatology/keac036 PMC 바로가기
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosisArticle Published on 2022-09-012022-11-15 Journal: Clinical Rheumatology [Category] [DOI] 10.1007/s10067-022-06219-7 PMC 바로가기
Persistent but atypical germinal center reaction among 3rd SARS-CoV-2 vaccination after rituximab exposureArticle Published on 2022-08-102022-11-15 Journal: Frontiers in Immunology [Category] [DOI] 10.3389/fimmu.2022.943476 PMC 바로가기
Role of booster with BNT162b2 mRNA in SARS-CoV-2 vaccination in patients with rheumatoid arthritis류마티스 관절염 환자에서 SARS-CoV-2 백신 접종에서 BNT162b2 mRNA를 포함한 부스터의 역할Article Published on 2022-08-012022-09-12 Journal: Immunologic research [Category] [DOI] 10.1007/s12026-022-09283-y PMC 바로가기 [Article Type] Article
Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis코로나바이러스 질병-19 백신에 대한 체액 반응은 류마티스 관절염 환자에서 리툭시맙의 투여량 및 시기에 따라 달라집니다Observational Study Published on 2022-06-282022-09-12 Journal: Rheumatology (Oxford, England) [Category] [DOI] 10.1093/rheumatology/keac206 PMC 바로가기 [Article Type] Observational Study
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients리툭시맙 치료 환자에서 COVID-19 백신 접종에 대한 체액 반응 장애의 위험 요인Observational Study Published on 2022-06-282022-09-11 Journal: Rheumatology (Oxford, England) [Category] [DOI] 10.1093/rheumatology/keab815 PMC 바로가기 [Article Type] Observational Study
Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions실생활에서 자가면역 염증성 류마티스 질환 환자의 코로나19 예방접종에 대한 체액 및 세포 반응Observational Study Published on 2022-06-282022-09-12 Journal: Rheumatology (Oxford, England) [Category] [DOI] 10.1093/rheumatology/keac089 PMC 바로가기 [Article Type] Observational Study
Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases리툭시맙은 자가면역 질환에서 COVID-19 백신에 대한 B 세포 반응을 손상시키지만 T 세포 반응을 손상시키지 않습니다Article Published on 2022-06-012022-09-12 Journal: Arthritis & rheumatology (Hoboken, N.J.) [Category] [DOI] 10.1002/art.42058 PMC 바로가기 [Article Type] Article
B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With RituximabB 세포 번호는 리툭시맙으로 치료받은 환자의 SARS-CoV-2 백신 접종 시 체액 및 세포 반응을 예측합니다Article Published on 2022-06-012022-09-12 Journal: Arthritis & rheumatology (Hoboken, N.J.) [Category] [DOI] 10.1002/art.42060 PMC 바로가기 [Article Type] Article
High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients벨리무맙 및 리툭시맙 수혜자에서 COVID-19 백신 접종 후 높은 T 세포 반응률Article Published on 2022-05-012022-09-11 Journal: Journal of autoimmunity [Category] [DOI] 10.1016/j.jaut.2022.102827 PMC 바로가기 [Article Type] Article